Alvotech (NASDAQ:ALVO) solidified its global commercialization strategy on Monday, entering into new supply and marketing agreements with Sandoz to bring a suite of biosimilar candidates to Canada, Australia, and New Zealand.
The partnership leverages Alvotech’s vertically integrated manufacturing in Iceland alongside Sandoz’s established regulatory and commercial infrastructure in these key pharmaceutical markets.
The agreements are split across distinct therapeutic areas and geographies.
In Canada, the deal focuses on a single ophthalmology biosimilar candidate, notably provided in a prefilled syringe for intravitreal injection.
For the Australian and New Zealand markets, the collaboration encompasses three biosimilar candidates targeting immunology and gastroenterology, covering multiple formulations to address chronic inflammatory and digestive conditions.
Under the terms of the deals, Sandoz will take the lead on all regulatory filings, local commercialization, and distribution efforts.
Alvotech will retain responsibility for all ongoing development and global clinical activities.
Critically, Alvotech will remain the exclusive manufacturer, supplying the finished products from its state-of-the-art facility in Reykjavik.
This expansion follows Alvotech's recent trend of securing early commercial pathways to ensure rapid market entry following regulatory approvals.